Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences to gain access to povetacicept, which is designed to treat IgA nephropathy and will be assessed in a Phase 3 trial in the second half of 2024. The cash deal is valued at $4.9 billion, with each share worth $65.